Evidence of a Correlation between CA15.3 and Estradiol Serum Levels in Women with Fibrocystic (non Macrocystic) Mastopathy

Pons Anicet D.M.F. , Krebs B.P. , Mira R. , Namer M. Value of CA15.3 in the follow-up of breast cancer patients. Br J Cancer 1987, 55: 567–9.

Colomer R. , Ruibal A. , Genollà J. Circulating CA15.3 levels in the postsurgical follow-up of breast cancer patients and in non malignant diseases. Breast Cancer Res Treat 1989, 13: 123–33.

Koliyanni A. , Mylonakis B. , Lazaridis I. Effect of therapy on benign mastopathy in the levels of CA15.3 antigen. I International Congress, Senologia, Athens 1988.

Koliyanni A. , Mylonakis B. , Lazaridis I. Hormone profile LH-RH factors, SHBG and CA15.3 levels in benign mastopathy. I International Congress, Senologia, Athens 1988.

Lundy J. , Schuss A. , Stanik O. , Sadri D. The CA15.3 assay in patients with benign breast disease and operable breast cancer. Proc. ASCO 1988.

Vizoso F. , Allende MaT , Fueyo A. , Vigal G. , Garcia Moran M. , Ruibal A. CA15.3 behaviour in patients with breast cystic diseases. Int J Biol Markers 1989, 4: 181–2.

Vizoso F. , Allende MaT , Fueyo A. , Vivanco J. Correlación entre las concentraciones séricas de CA15.3 y estradiol en mujeres afectas de enfermedad macro-quística de la mama. Med Clin 1990, 84: 789.